宣肺通络方治疗小儿肺炎支原体肺炎的疗效及对炎症因子、sIgA、hBD2和CAL的影响  

Efficacy of Xuanfei Tongluo Formula in the Treatment of Children with Mycoplasma Pneumoniae Pneumonia and Its Effects on Inflammatory Factors,sIgA,hBD2 and CAL

作　　者：狄雯雯[1] 陆影[1] 詹红艳[1] DI Wenwen;LU Ying;ZHAN Hongyan(Dept.of Pediatrics,the Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine,Changsha 410005,China)

机构地区：[1]湖南中医药大学第二附属医院门诊儿科,长沙410005

出　　处：《中国医院用药评价与分析》2023年第2期178-181,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：湖南省中医药科研计划项目(No.201789)。

摘　　要：目的:探讨宣肺通络方治疗小儿肺炎支原体肺炎(MPP)的临床疗效。方法:选择2020年1月至2022年3月该院儿科收治的MPP患儿90例,按照随机数字表法分为治疗组和对照组,每组45例。对照组患儿予以西医常规治疗,包括吸氧、雾化吸入和补充液体等,并给予阿奇霉素序贯疗法;治疗组患儿在对照组治疗的基础上予以中药宣肺通络方口服,疗程均为2周。比较两组患儿治疗前后的中医证候评分,肺功能指标[第1秒最大呼气容积(FEV_(1))、呼气流量峰值(PEF)、用力肺活量(FVC)和FEV_(1)/FVC]、血清烟酰胺磷酸核糖基转移酶(NAMPT)、人类软骨糖蛋白39(YKL-40)、白细胞介素8(IL-8)水平和唾液分泌型免疫球蛋白A(sIgA)、人β-防御素2(hBD2)及粪钙卫蛋白(CAL)含量,比较两组患儿治疗总有效率和不良反应发生率。结果:治疗后,治疗组患儿咳嗽、喘息、唇绀和发热评分均低于对照组(P<0.01),FEV_(1)、PEF和FEV_(1)/FVC水平高于对照组(P<0.01),血清NAMPT、YKL-40、IL-8水平低于对照组(P<0.01),唾液sIgA含量高于对照组(P<0.01),唾液hBD2、粪CAL含量低于对照组(P<0.01),差异均有统计学意义。治疗组患儿的总有效率为95.56%(43/45),高于对照组的82.22%(37/45),差异有统计学意义(P<0.05)。治疗组患儿治疗期间的不良反应发生率为6.67%(3/45),低于对照组的22.22%(10/45),差异有统计学意义(P<0.05)。结论:宣肺通络方可降低MPP患儿的中医证候评分,改善肺功能,提高气道免疫功能,抑制炎症因子表达,减少唾液内hBD2、粪CAL含量,治疗效果显著。OBJECTIVE:To probe into the clinical of Xuanfei Tongluo formula in the treatment of children with Mycoplasma pneumoniae pneumonia(MPP).METHODS:A total of 90 children with MPP admitted into the department of pediatrics of the hospital from Jan.2020 to Mar.2022 were extracted to be divided into the treatment group and control group via the random number table method,with 45 cases in each group.The control group was treated with conventional western medicine,including oxygen inhalation,atomization inhalation,liquid supplement,and azithromycin sequential therapy.The treatment group received Xuanfei Tongluo formula on the basis of the control group,and the course of treatment was 2 weeks.Before and after treatment,the traditional Chinese medicine syndrome score,pulmonary function indicators[maximum expiratory volume at one second(FEV_(1)),peak expiratory flow(PEF),forced vital capacity(FVC),FEV_(1)/FVC],the contents of serum nicotinamide phosphoribosyltransferase(NAMPT),human cartilage glycoprotein 39(YKL-40),interleukin-8(IL-8),salivary secretory immunoglobulin A(sIgA)and humanβ-defensin 2(hBD2)and fecal calprotectin(CAL)of two groups were compared.The total effective rate and incidence of adverse drug reactions were compared between two groups.RESULTS:After treatment,the scores of cough,wheezing,cyanosis and fever in the treatment group were lower than those in the control group(P<0.01),FEV_(1),PEF and FEV_(1)/FVC were higher than those in the control group(P<0.01),and the serum levels of NAMPT,YKL-40 and IL-8 were lower than those in the control group(P<0.01),the salivary sIgA was significantly higher than that in the control group(P<0.01),and the salivary hBD2 and fecal CAL were significantly lower than those in the control group(P<0.01),with statistically significant differences.The total effective rate of the treatment group was 95.56%(43/45),higher than 82.22%(37/45)of the control group,the difference was statistically significant(P<0.05).The incidence of adverse drug reactions in the treatment group was 6.67%

关 键 词：肺炎支原体肺炎 中药 宣肺通络方 炎症因子 

分 类 号：R932[医药卫生—生药学] R978.1[医药卫生—药学]